Sign in
CompletedNo phase

Coordinating Opioid Use Treatment Through Medical Management With Infection Treatment (Project COMMIT)

Key facts

Who runs it
Yale University
Where
Greenville, Hershey, and New Haven, United StatesSee the 3 sites
Trial code
Status
Completed
People taking part
171 people enrolled
Started
18 Aug 2020
Ended
25 Apr 2024
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • ID/LAB
  • TAU
Record updated
14 July 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Adults able to provide written informed consent in English or Spanish
  • Current hospitalization with a suspected or known bacterial or viral (HIV/HCV/HBV) infection including but not limited to bacteremia, Candidal fungemia, osteomyelitis, endophthalmitis, septic thrombophlebitis, infected pseudoaneurysm, endocarditis, skin/soft tissue infection (SSTI), or septic arthritis
  • Current moderate-to-severe OUD (DSM-5)
  • Willing to accept assignment to either ID/LAB or TAU, and to participate in research follow-up visits

Who cannot take part

  • Severe medical or psychiatric disability making participation unsafe (e.g. imminent suicide risk)
  • Allergy, hypersensitivity or medical contraindication to buprenorphine
  • Moderate-severe liver impairment in the judgment of the study investigator
  • Pregnancy, planning conception, or breast-feeding for female participants
  • Preexisting enrollment on methadone or buprenorphine (SL-B) maintenance AND intending to remain on methadone or buprenorphine maintenance upon discharge (patients already under effective treatment for OUD do not represent the target population of untreated OUD patients entering hospitals, nor would we want to disrupt established effective treatment)
  • Inability or unwillingness of subject to give informed consent

Where in United States

  • Prisma HealthGreenville, United States
  • Penn State Health Milton S. Hershey Medical CenterHershey, United States
  • Yale New Haven HospitalNew Haven, United States

About the trial

What the trial wants to find out

This study seeks to test a new model of care (ID/LAB) in which opioid use disorder (OUD) is managed by infectious disease (ID) specialists and hospitalists concurrent with management of the OUD-related infections, using long-acting injectable buprenorphine (LAB), followed by referral as soon as possible after hospital discharge to community resources for long term treatment of OUD.

The 2 groups in the trial

  • TAUExisting treatment, for comparison

    Treatment as Usual (TAU).

  • ID/LABTreatment being tested

    Infectious Disease management of OUD with Long-Acting injectable buprenorphine (ID/LAB).

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Publications
Record updated
14 July 2026